Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...
Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on ...
While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...
Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...
Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback